 RUTHERFORD, N.J., Feb. 16, 2021 GLOBE NEWSWIRE -- Cancer Genetics, Inc. the Company Nasdaq: CGIX, a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced the closing of its previously announced registered direct offering with several healthcare-focused institutional investors of 2,777,778 shares of its common stock at a purchase price of 6.30 per share, priced at-the-market under Nasdaq rules. The gross proceeds to the Company from the offering totaled approximately 17.5 million, before deducting placement agent fees and offering expenses. 